Collectively, targeting the CD47–TSP1 axis represents a new disease-modifying therapeutic direction for AAA that could complement or delay surgical intervention and ultimately lay the foundation for the first effective pharmacological approach in AAA management. The gene discussed is THBS1; the disease is triple-A syndrome.